NKGen Biotech (NKGN) announced the presentation of two posters, on its first-in-kind, autologous, non-genetically modified NK cell product, troculeucel, in Alzheimer’s Disease, AD. The posters entitled, “Use of Non-genetically Modified Natural Killer Cells, SNK01, With Enhanced Activity in Subjects with Active Alzheimer’s Disease. Further Biomarker Analysis and Implications for Use in Prevention” and “Treatment of Moderate Alzheimer’s Disease Subjects with Expanded Non-genetically Modified Natural Killer Cells with Enhanced Activity – Report of the Phase 1 results of the Phase 1/2a Study” were presented at the 17th Clinical Trials on Alzheimer’s Disease Annual Meeting, CTAD, on October 29, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NKGN:
- NKGen Biotech Welcomes New Directors and Assigns Committees
- NKGen Biotech Announces Leadership Shuffle on Anniversary
- NKGen Biotech announces early interim data from Phase 1 cohort
- NKGen Biotech Expands Agreement Terms and Restructures COO Role
- NKGen Biotech to Showcase at Global Investment Conference
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
